# TROPHY U-01 Study:

TROPHY U-01

## A Phase 2 Open-Label, Study of Sacituzumab Govitecan (SG) in Metastatic Urothelial Cancer (mUC) After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy

## Study Design

Trial registration number: NCT03547973




*Per RECIST v1.1

## Enrollment and key eligibility criteria

Key Inclusion Criteria:

- ECOG of 0 or 1;
- Cohorts 1-3: Creatinine clearance ≥30 mL/min; Cohorts 4-5: Creatinine clearance ≥50 mL/min
- Adequate organ function and stable brain metastases

Key Exclusion Criteria:

- Immunodeficiency,
- Active Hepatitis B or C,
- Active secondary malignancy

## Questions?

- For more information on the TROPHY-01 Study, please contact GileadClinicalTrials@gilead.com

**Safety and efficacy have not been demonstrated for the investigational uses described here. There is no guarantee that the investigational therapies or uses will be approved for use.**
**Visit clinicaltrials.gov for more information. Clinicaltrials.gov: NCT03547973**

CBR, clinical benefit rate; Cis, cisplatin; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; ORR, objective response rate; OS, overall survival; PD-1, programmed cell death-1; PD-L1, programmed death-ligand 1; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors, version 1.1; 1L, first line; 2L, second line

**References**:
National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT03547973. Accessed December 17, 2021.
Gilead Sciences Data on File.

GILEAD Oncology